From Prioritization to Universal Treatment : Successes and Challenges of Hepatitis C Virus Elimination in Italy
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
Italy has had the highest prevalence of hepatitis C virus (HCV) infection and mortality from HCV-related liver cancer in Europe. Although direct-acting antivirals (DAA) were initially restricted to persons with advanced fibrosis, their use has since been extended to all infected individuals; more than 244 000 persons have been treated to date. HCV liver-related mortality is expected to decline by 75% by 2030, achieving the World Health Organization target for mortality. However, Italy risks failing to meet the overall goal of eliminating HCV infection by 2030. In this light, €71.5 million have been allocated for screening initially specific target populations (persons who inject drugs, prison inmates, and the 1969-1989 birth cohort). Herein, we outline the challenges and recommendations for how to move Italy toward HCV elimination, including expanding screening programs in other populations, increasing awareness through strategic communication, sustaining DAA access, and tailoring care models to meet the needs of key populations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:228 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 228(2023), Suppl 3 vom: 13. Sept., Seite S211-S220 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kondili, Loreta A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 15.09.2023 Date Revised 22.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiad038 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362006679 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362006679 | ||
| 003 | DE-627 | ||
| 005 | 20231226090335.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiad038 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1206.xml |
| 035 | |a (DE-627)NLM362006679 | ||
| 035 | |a (NLM)37703346 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kondili, Loreta A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a From Prioritization to Universal Treatment |b Successes and Challenges of Hepatitis C Virus Elimination in Italy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.09.2023 | ||
| 500 | |a Date Revised 22.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a Italy has had the highest prevalence of hepatitis C virus (HCV) infection and mortality from HCV-related liver cancer in Europe. Although direct-acting antivirals (DAA) were initially restricted to persons with advanced fibrosis, their use has since been extended to all infected individuals; more than 244 000 persons have been treated to date. HCV liver-related mortality is expected to decline by 75% by 2030, achieving the World Health Organization target for mortality. However, Italy risks failing to meet the overall goal of eliminating HCV infection by 2030. In this light, €71.5 million have been allocated for screening initially specific target populations (persons who inject drugs, prison inmates, and the 1969-1989 birth cohort). Herein, we outline the challenges and recommendations for how to move Italy toward HCV elimination, including expanding screening programs in other populations, increasing awareness through strategic communication, sustaining DAA access, and tailoring care models to meet the needs of key populations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HCV | |
| 650 | 4 | |a HCV model of care | |
| 650 | 4 | |a PWID | |
| 650 | 4 | |a WHO elimination targets | |
| 650 | 4 | |a global burden of disease | |
| 650 | 4 | |a inmates | |
| 650 | 4 | |a linkage to care | |
| 650 | 4 | |a public health | |
| 650 | 4 | |a screening | |
| 650 | 4 | |a viral hepatitis elimination | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Craxì, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Nava, Felice |e verfasserin |4 aut | |
| 700 | 1 | |a Babudieri, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a D'Ambrosio, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Marcellusi, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Mennini, Francesco Saverio |e verfasserin |4 aut | |
| 700 | 1 | |a Valle, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Pierluigi |e verfasserin |4 aut | |
| 700 | 1 | |a Olimpieri, Pier Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Andreoni, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Aghemo, Alessio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 228(2023), Suppl 3 vom: 13. Sept., Seite S211-S220 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:228 |g year:2023 |g number:Suppl 3 |g day:13 |g month:09 |g pages:S211-S220 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiad038 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 228 |j 2023 |e Suppl 3 |b 13 |c 09 |h S211-S220 | ||